Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Estonia

European Innovation Council · Running

KevadBio Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)

Coordinator
Genecode AS, Estonia
Runs
1 January 2024 to 31 December 2026
Status
Running
EU funding
€1.6m
Total cost
€2.3m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190151095

What the project is doing

In the project's own words, from its summary on CORDIS.

GeneCode is developing a novel anti-PD drug that contains a central nervous system penetrant compound imitating GDNF peptide pathway activation that alleviates both motor and non-motor symptoms in PD patients, protecting and restoring lesioned dopamine neurons as well as potentially increasing dopamine levels in brain tissue. GeneCode’s unique solution uses small-molecule compounds that penetrate the blood-brain barrier, target the GFL receptor complex (containing GDNF protein) and mimic GFL (GNDF family of ligands) biological effects in neurons, promoting survival in the affected dopaminergic neuronal pathways.

Once fully developed, the PD drug would be administered weekly or less frequently as an oral treatment. Considering the importance of GDNF family ligands and/or RET-signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited to PD, but can be applied to cure other medical conditions such as neuropathic pain, addiction, ALS etc.

Topics

Who is involved

OrganisationCityCountryRole
Genecode ASTallinnEstoniaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI